Image (E33fdabd C42d 47bf Af0a 1b6d3637f519 01)
Desvenlafaxine Succinate Tablet, Film Coated, Extended Release
Product Images NDC 71335-1331
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine Succinate (NDC 71335-1331). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image (E33fdabd C42d 47bf Af0a 1b6d3637f519 02)
Image (E33fdabd C42d 47bf Af0a 1b6d3637f519 03)
The text describes a figure labeled "Figure 2" which shows the effect of other drugs on the pharmacokinetics of Desvenlafaxine. The figure includes information on the geometric mean ratio with a confidence interval of 90%. The drugs mentioned are CYP3A4 inhibitors such as Ketoconazole. There is also a graph showing changes in AUC. It is unclear what the reference is for this information.*
Image (E33fdabd C42d 47bf Af0a 1b6d3637f519 04)
The text provides pharmacokinetic data related to the effects of Desvenlafaxine on other drugs. It includes the geometric mean ratio at 90% confidence interval for drugs metabolized by CYP2D6, CYP3A, and CYP2D6&CYP3M substrates. The data is presented in the form of a table with results for Tamoxifen active metabolite Endroxifen and Aripiprazole active metabolite dehydro-aripiprazole.*
Image (E33fdabd C42d 47bf Af0a 1b6d3637f519 05)
The figure shows the estimated proportion of patients experiencing a relapse over time in Study 5. The horizontal axis represents the number of days since randomization and the vertical axis represents the estimated proportion of relapses, with values ranging from 0% to 50%. The blue line represents the treatment group receiving Desvenlafaxine extended-release tablets 50 mq, while the orange line represents the placebo group. The graph suggests that the Desvenlafaxine group had a lower proportion of relapse cases over time compared to the placebo group.*
Image (E33fdabd C42d 47bf Af0a 1b6d3637f519 06)
This appears to be a graph depicting the estimated proportion of patients experiencing relapse over time (measured in days) from randomization, with one line representing Desvenlafaxine extended-release tablets and the other representing a placebo. The percentage values for the proportion of patients are not available due to the limitations of .*
Label (Lbl713351331)
This is a medication package label. It contains information on the medication and dosage instructions. The medication is called Pristig, a 100mg tablet, and is produced by Lupin Limited. The package contains 30 tablets and has an expiry date of MM/YY. The National Drug Code (NDC) is 7133513311. The medication should be stored in a room temperature of 20°-25°C (68°-77°F). The package also includes a warning to keep all drugs out of children's reach. The rest of the text appears to be errors generated by .*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
